Chief Healthcare Executive October 22, 2024
Ron Southwick

Robert Califf talked about the difficulties in regulating AI technologies, why he fears AI could exacerbate inequities, and the need for a better supply chain.

Las Vegas – With the growth of artificial intelligence and other technologies evolving so rapidly, Robert Califf says the Food and Drug Administration is going to have to change as well.

The FDA commissioner outlined the challenge during a 20-minute conversation at the HLTH conference Monday.

“We’re entering an era where we’re going to have to rethink everything we do because of the technology changes that we’re seeing, which affect every single industry that we’re dealing with,” Califf said.

The FDA is dealing with the difficulties of the rapid growth in AI technology. As Califf...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Conferences / Podcast, FDA, Govt Agencies, Trends
Google’s Pixel Watch 3 Loss of Pulse Detection Feature Receives FDA Clearance
FDA Annual Flu Vaccine Meeting and CDC’s ‘Wild to Mild’ Campaign Canceled
Supporting the Development of Drugs for Rare Diseases — The Importance of Regulatory Transparency
Opinion: To fight for those with rare diseases, Trump must reform and modernize the FDA thoughtfully
5 Rare Diseases That Now Have Their First FDA-Approved Treatments

Share This Article